Tariq A Hammad1, Aaron P Thrift2, Hashem B El-Serag3,4, Nisreen S Husain1,5. 1. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine Medical Center, McNair Campus, 7200 Cambridge St., 8th Floor, Suite 8B, Houston, TX, 77030, USA. 2. Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 3. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine Medical Center, McNair Campus, 7200 Cambridge St., 8th Floor, Suite 8B, Houston, TX, 77030, USA. hasheme@bcm.edu. 4. Section of Gastroenterology and Hepatology, Michael E. DeBakey VA Medical Center (MEDVAMC), Houston, TX, USA. hasheme@bcm.edu. 5. Section of Gastroenterology and Hepatology, Michael E. DeBakey VA Medical Center (MEDVAMC), Houston, TX, USA.
Abstract
BACKGROUND: Barrett's esophagus (BE) is the premalignant lesion of esophageal adenocarcinoma (EAC) and is the target of early detection and prevention efforts for EAC. AIMS: We sought to evaluate what proportion and temporal trends of EAC patients had missed opportunities for screening and surveillance of BE. METHODS: Our study included 182 patients with EAC at the Michael E. DeBakey VA Medical Center in Houston, Texas, between 02/2005 and 09/2017. We conducted a retrospective audit of patients' medical records for any previous upper endoscopies (EGDs) for screening or surveillance of BE prior to their EAC diagnosis. RESULTS: The mean age of the cohort was 67.3 years (SD = 9.5); 99.5% of patients were male, and 85.2% were white. Only 45 patients (24.7%) had EGD at any time prior to the cancer diagnosing EGD, of whom 29 (15.9% of all EAC cases) had an established BE diagnosis. In the 137 patients with no prior EGD, most (63.5%) had GERD or were obese or ever smokers. There were no changes in patterns over time. For the 29 patients with prior established BE, 22 (75.8%) were diagnosed with EAC as a result of surveillance EGD. Patients with prior established BE were more likely to be diagnosed at 0 or I stage (p < 0.001) and managed with endoscopic or surgical modalities (p < 0.001) than patients without prior BE. CONCLUSIONS: Despite having established risk factors for BE, the majority of EAC patients had no prior EGD to screen for BE. BE screening may represent the largest missed opportunity to reduce EAC mortality.
BACKGROUND:Barrett's esophagus (BE) is the premalignant lesion of esophageal adenocarcinoma (EAC) and is the target of early detection and prevention efforts for EAC. AIMS: We sought to evaluate what proportion and temporal trends of EACpatients had missed opportunities for screening and surveillance of BE. METHODS: Our study included 182 patients with EAC at the Michael E. DeBakey VA Medical Center in Houston, Texas, between 02/2005 and 09/2017. We conducted a retrospective audit of patients' medical records for any previous upper endoscopies (EGDs) for screening or surveillance of BE prior to their EAC diagnosis. RESULTS: The mean age of the cohort was 67.3 years (SD = 9.5); 99.5% of patients were male, and 85.2% were white. Only 45 patients (24.7%) had EGD at any time prior to the cancer diagnosing EGD, of whom 29 (15.9% of all EAC cases) had an established BE diagnosis. In the 137 patients with no prior EGD, most (63.5%) had GERD or were obese or ever smokers. There were no changes in patterns over time. For the 29 patients with prior established BE, 22 (75.8%) were diagnosed with EAC as a result of surveillance EGD. Patients with prior established BE were more likely to be diagnosed at 0 or I stage (p < 0.001) and managed with endoscopic or surgical modalities (p < 0.001) than patients without prior BE. CONCLUSIONS: Despite having established risk factors for BE, the majority of EACpatients had no prior EGD to screen for BE. BE screening may represent the largest missed opportunity to reduce EAC mortality.
Authors: Hashem B El-Serag; Aanand D Naik; Zhigang Duan; Mohammad Shakhatreh; Ashley Helm; Amita Pathak; Marilyn Hinojosa-Lindsey; Jason Hou; Theresa Nguyen; John Chen; Jennifer R Kramer Journal: Gut Date: 2015-08-26 Impact factor: 23.059
Authors: Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen Journal: Gastroenterology Date: 2011-03 Impact factor: 22.682
Authors: V Raman Muthusamy; Jenifer R Lightdale; Ruben D Acosta; Vinay Chandrasekhara; Krishnavel V Chathadi; Mohamad A Eloubeidi; Robert D Fanelli; Lisa Fonkalsrud; Ashley L Faulx; Mouen A Khashab; John R Saltzman; Aasma Shaukat; Amy Wang; Brooks Cash; John M DeWitt Journal: Gastrointest Endosc Date: 2015-04-08 Impact factor: 9.427
Authors: Nastazja Dagny Pilonis; Sarah Killcoyne; W Keith Tan; Maria O'Donovan; Shalini Malhotra; Monika Tripathi; Ahmad Miremadi; Irene Debiram-Beecham; Tara Evans; Rosemary Phillips; Danielle L Morris; Craig Vickery; Jon Harrison; Massimiliano di Pietro; Jacobo Ortiz-Fernandez-Sordo; Rehan Haidry; Abigail Kerridge; Peter D Sasieni; Rebecca C Fitzgerald Journal: Lancet Oncol Date: 2022-01-11 Impact factor: 41.316